Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: End of beginning or beginning of end?

Expert Opinion on Biological Therapy

Volumn 13, Issue 11, 2013, Pages 1515-1522

  Li, Yun ^a   Liu, Yahong ^a   Wang, Zhaojun ^a   Jiang, Yongjun ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Amyloid; Clinical trials; Immunotherapy; Tau

Indexed keywords

AFFITOPE; ALZHEIMER DISEASE VACCINE; AMYLOID; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BAPINEUZUMAB; CAD 106; CAD106; GANTACURIUM; IMMUNOGLOBULIN; QS 21; SOLANEZUMAB; TAU PROTEIN; UNCLASSIFIED DRUG; VANUTIDE CRIDIFICAR;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY RESPONSE; DISEASE SEVERITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOTHERAPY; MENINGOENCEPHALITIS; NONHUMAN; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY SPECIFICITY; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNIZATION; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; PHOSPHORYLATION; PLAQUE, AMYLOID; PLASMA EXCHANGE; PLASMAPHERESIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAU PROTEINS;

EID: 84885649629     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.838555     Document Type: Review

References (63)

1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006á368:387-403
2. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010 362:329-44
3. Lalonde R, Fukuchi K, Strazielle C. Neurologic and motor dysfunctions in APP transgenic mice. Rev Neurosci 2012á23:363-79
4. Morales-Corraliza J, Schmidt SD, Mazzella MJ, et al. Immunization targeting a minor plaque constituent clears beta-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model. Neurobiol Aging 2013á34:137-45
5. Gandy S. Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease. Neurobiol Aging 2002á23:1009-16
6. Weiner HL, Selkoe DJ. Inflammation and therapeutic vaccination in CNS diseases. Nature 2002á420:879-84
7. Jiang Y, Zhu J, Xu G, et al. Intranasal delivery of stem cells to the brain. Expert Opin Drug Deliv 2011á8:623-32
8. Jiang Y, Wei N, Lu T, et al. Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience 2011á172:398-405
9. Hong L, Koelsch G, Lin X, et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 2000á290:150-3
10. Citron M. Alzheimer's disease: Treatments in discovery and development. Nat Neurosci 2002á5(Suppl):1055-7
11. Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 2012á32:9677- 89
12. Wang W, Fan L, Xu D, et al. Immunotherapy for Alzheimer's disease. Acta Biochim Biophys Sin (Shanghai) 2012á44:807-14
13. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000á408:982-5
14. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999á400:173-7
15. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: The end of the beginning. Nat Rev Neurosci 2002á3:824-8
16. Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42(AN1792) in patients with AD. Neurology 2005á64:94-101
17. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008á372:216-23
18. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol 2002á1:3
19. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003á61:46-54
20. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005á64:1553-62
21. Fox NC, Black RS, Gilman S, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005á64:1563-72
22. Vellas B, Black R, Thal LJ, et al. Long-term follow-up of patients immunized with AN1792: Reduced functional decline in antibody responders. Curr Alzheimer Res 2009á6:144-51
23. Serrano-Pozo A, William CM, Ferrer I, et al. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 2010 133:1312-27
24. Boche D, Donald J, Love S, et al. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol 2010 120:13-20
25. Robinson SR, Bishop GM, Lee HG, et al. Lessons from the AN 1792 Alzheimer vaccine: Lest we forget. Neurobiol Aging 2004á25:609-15
26. Schenk D. Hopes remain for an Alzheimer's vaccine. Nature 2004á431:398
27. Chackerian B. Virus-like particle based vaccines for Alzheimer disease. Hum Vaccin 2010 6:926-30
28. Wiessner C, Wiederhold KH, Tissot AC, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011á31:9323-31
29. Winblad B, Andreasen N, Minthon L, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: Randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012á11:597-604
30. Kingwell K. Alzheimer disease: Amyloid-beta immunotherapy CAD106 passes first safety test in patients with Alzheimer disease. Nat Rev Neurol 2012á8:414
31. Schneeberger A, Mandler M, Otawa O, et al. Development of AFFITOPE vaccines for Alzheimer's disease (AD)- from concept to clinical testing. J Nutr Health Aging 2009á13:264-7
32. Weksler ME, Relkin N, Turkenich R, et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002á37:943-8
33. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012á367:2015-25
34. Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004á75:1472-4
35. Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009á30:1728-36
36. Dodel R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: A phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013á12:233-43
37. Holmes C. Intravenous immunoglobulin for Alzheimer's disease. Lancet Neurol 2013á12:218-19
38. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009á73:2061-70
39. Black RS, Sperling RA, Safirstein B, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010 24:198-203
40. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011á7:367-85
41. Archer HA, Edison P, Brooks DJ, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C-PIB positron emission tomography study. Ann Neurol 2006á60:145-7
42. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010 9:363-72
43. Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012á69:1002-10
44. Vellas B, Carrillo MC, Sampaio C, et al. Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force. Alzheimers Dement 2013á9:438-44
45. Tayeb HO, Murray ED, Price BH, et al Bapineuzumab and solanezumab for Alzheimer's disease: Is the 'amyloid cascade hypothesis' still alive? Expert Opin Biol Ther 2013á13:1075-84
46. Uenaka K, Nakano M, Willis BA, et al. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid beta monoclonal antibody solanezumab in Japanese and white patients with mild to moderate Alzheimer disease. Clin Neuropharmacol 2012á35:25-9
47. Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 2012á8:261-71
48. Lachno DR, Evert BA, Vanderstichele H, et al. Validation of assays for measurement of amyloid-beta peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab. J Alzheimers Dis 2013á34:897-910
49. Gray LJ, Cooper N, Dunkley A, et al. A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. Obes Rev 2012á13:483-98
50. Samadi H, Sultzer D. Solanezumab for Alzheimer's disease. Expert Opin Biol Ther 2011á11:787-98
51. Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: A novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis 2012á28:49-69
52. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012á69:198-207
53. Grundman M, Dibernardo A, Raghavan N, et al. 2012: A watershed year for. Alzheimer's disease research. J Nutr Health Aging 2013á17:51-3
54. Reichert JM. Which are the antibodies to watch in 2013? MAbs 2013á5:1-4
55. Jiang Y, Zhu W, Zhu J, et al. Feasibility of delivering mesenchymal stem cells via catheter to the proximal end of lesion artery in patients with stroke in the territory of middle cerebral artery. Cell Transplant 2012á [Epub ahead of print
56. Ma YP, Ma MM, Ge S, et al. Intranasally delivered TGF-beta1 enters brain and regulates gene expressions of its receptors in rats. Brain Res Bull 2007á74:271-7
57. Alcalá-Barraza SR, Lee MS, Hanson LR, et al. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target 2010 18:179-90
58. Hashizume R, Ozawa T, Gryaznov SM, et al. New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 2008á10:112-20
59. Bondier JR, Michel G, Propper A, et al. Harmful effects of cadmium on olfactory system in mice. Inhal Toxicol 2008á20:1169-77
60. Jiang Y, Wei N, Zhu J, et al. A new approach with less damage: Intranasal delivery of tetracycline-inducible replication-defective herpes simplex virus type-1 vector to brain. Neuroscience 2012á201:96-104
61. Han IK, Kim MY, Byun HM, et al. Enhanced brain targeting efficiency of intranasally administered plasmid DNA: An alternative route for brain gene therapy. J Mol Med 2007á85:75-83
62. Frenkel D, Solomon B. Filamentous phage as vector-mediated antibody delivery to the brain. Proc Natl Acad Sci USA 2002á99:5675-9
63. Liu X. Clinical trials of intranasal delivery for treating neurological disorders - A critical review. Expert Opin Drug Deliv 2011á8:1681-90